CJC-1295 / Ipamorelin Blend
Also known as: CJC-1295 / Ipamorelin Blend, GH Stack
The most popular GH-peptide combination, pairing a GHRH analog (CJC-1295) with a selective ghrelin agonist (ipamorelin) to produce a strong, clean, synergistic growth hormone pulse.
Last updated
Mechanism of Action
This blend combines CJC-1295, a GHRH-receptor agonist that increases the amplitude of GH synthesis and release, with ipamorelin, a selective GHS-R1a (ghrelin) agonist that triggers a clean GH pulse. Because the two act on separate receptor pathways, their combined stimulation of the pituitary is synergistic rather than additive. Ipamorelin's selectivity keeps cortisol and prolactin low while CJC-1295 sustains the elevated GH/IGF-1 signal.
- Half-life
- Combined: ipamorelin ~2 hours; CJC-1295 no-DAC ~30 min or DAC ~days
- Administration Routes
- subcutaneous
- Research Status
- Research Chemical
Reported Benefits
- Synergistic GH pulse from two receptor pathways
- Clean profile with minimal cortisol/prolactin elevation
- Supports lean mass, recovery, and fat metabolism
- May improve sleep quality
- Convenient single combined preparation
Potential Side Effects
- Water retention and tingling in extremities
- Injection-site irritation
- Head-rush or flushing after dosing
- Possible impact on insulin sensitivity with prolonged use
Common Dosing
Research protocols commonly reference ~100 mcg each per dose, 1-3 times daily, often before sleep and post-workout. Educational reference only.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Active malignancy
- Uncontrolled diabetes
- Pregnancy or breastfeeding
- Not approved for human therapeutic use
CJC-1295
A long-acting growth hormone releasing hormone (GHRH) analog that stimulates the pituitary to produce more growth hormone. Often paired with a ghrelin mimetic for synergistic GH release.
Ipamorelin
A selective ghrelin receptor agonist (growth hormone secretagogue) prized for stimulating GH release with minimal effect on cortisol or prolactin. Considered one of the gentler GH peptides.
MK-677
An orally active, non-peptide ghrelin receptor agonist that raises GH and IGF-1 levels. Notable for being a daily oral compound rather than an injectable.
- View
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
2006
- View
Ipamorelin, the first selective growth hormone secretagogue
1998
- View
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
2026